$141 Million is the total value of Tamarack Advisers, LP's 27 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GILD | New | GILEAD SCIENCES INCequity | $7,161,000 | – | 100,000 | +100.0% | 5.06% | – |
| LH | New | LABORATORY CRP OF AMER HLDGSequity | $6,547,000 | – | 51,000 | +100.0% | 4.63% | – |
| New | NOVOCURE LTDequity | $6,476,000 | – | 825,000 | +100.0% | 4.58% | – | |
| OBLN | New | OBALON THERAPEUTICS INCequity | $4,979,000 | – | 562,606 | +100.0% | 3.52% | – |
| AMGN | New | AMGEN INCequity | $4,533,000 | – | 31,000 | +100.0% | 3.21% | – |
| ATHN | New | ATHENAHEALTH INCequity | $4,312,000 | – | 41,000 | +100.0% | 3.05% | – |
| SCI | New | SERVICE CORP INTERNATIONALequity | $3,550,000 | – | 125,000 | +100.0% | 2.51% | – |
| IPXL | New | IMPAX LABORATORIES INCequity | $3,412,000 | – | 257,500 | +100.0% | 2.41% | – |
| BSX | New | BSX US 02/17/17 C19listed option | $635,000 | – | 2,200 | +100.0% | 0.45% | – |
| HSIC | New | HSIC US 01/20/17 P155listed option | $164,000 | – | 360 | +100.0% | 0.12% | – |
| SYK | New | SYK US 01/20/17 P115listed option | $27,000 | – | 250 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2017-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.